Company / Cash & Equivalents
SCYNEXIS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$21.3M
FY2025
5-year range
$16.1M / $104.5M
FY2021-FY2025
Trend
+32.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $21M.
Based on SEC 10-K filings.
$21M in FY2025 with a 5-year CAGR of -25.6%.
Declined from $34M to $21M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -22.6%
- 5-Year CAGR
- -25.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -25.6%, indicating a declining trend.
- In FY2025, cash & equivalents increased 32.4% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.39 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $21.3M | +32.4% |
| FY2024 | $16.1M | -52.9% |
| FY2023 | $34.0M | -25.7% |
| FY2022 | $45.8M | -56.2% |
| FY2021 | $104.5M | +12.3% |
| FY2020 | $93.0M | +121.9% |
| FY2019 | $41.9M | +266.5% |
| FY2018 | $11.4M | -0.3% |
| FY2017 | $11.5M | -75.6% |
| FY2016 | $47.0M | +3251.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026